| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 09/12/2002 | WO2002070557A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070511A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 09/12/2002 | WO2002070510A2 Amino dicarboxylic acid derivatives with pharmaceutical properties |
| 09/12/2002 | WO2002070502A1 Dimeric isoflavones |
| 09/12/2002 | WO2002070490A1 Agonists of beta-adrenoceptors |
| 09/12/2002 | WO2002070479A1 N-4-piperidinyl compounds as ccr5 modulators |
| 09/12/2002 | WO2002069993A1 Pharmaceutical composition made of cannabis extracts |
| 09/12/2002 | WO2002069970A1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| 09/12/2002 | WO2002069930A1 Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| 09/12/2002 | WO2002069908A2 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| 09/12/2002 | WO2002069899A2 Methods and compositions for the treatment and prevention of smooth muscle cell proliferation |
| 09/12/2002 | WO2002069740A1 Compositions containing creatine and creatinine |
| 09/12/2002 | WO2002012346A3 A new slit-like protein obtained from a cdna library from hs-5 stromal cell line |
| 09/12/2002 | WO2001096334A3 Heteroarylalkanoic acids as integrin receptor antagonists |
| 09/12/2002 | WO2001091766A3 Compositions for treating hand and wrist discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins |
| 09/12/2002 | WO2001089520A3 Dehydroascorbic acid formulations and uses thereof |
| 09/12/2002 | WO2001015700A9 POLYMORPHS OF N-METHYL-N-(3-{3-[2-THIENYLCARBONYL]-PYRAZOL-[1,5-α]-PYRIMIDIN -7-YL }PHENYL )ACETAMIDE AND COMPOSITIONS AND METHODS RELATED THERETO |
| 09/12/2002 | WO2001010203A3 Non-human transgenic animals for the study of neurodegenerative syndromes |
| 09/12/2002 | US20020129385 Medthods for improving long-term memory storage and retrieval |
| 09/12/2002 | US20020128471 Useful for treating cellular hyperproliferation |
| 09/12/2002 | US20020128306 Programmed cell death; expansion of hematopoietic cells, for prolonging viability of an organ for transplantation, and maintaining viability of cell lines used in bioproduction |
| 09/12/2002 | US20020128286 Isoindolyl and isoquinolinyl aroyl pyrrole compounds |
| 09/12/2002 | US20020128279 Potassium channel blocking agents |
| 09/12/2002 | US20020128263 Treatment or prevention of mGluR5 receptor mediated disorders. |
| 09/12/2002 | US20020127668 Polypeptide for use in the diagnosis and treatment of cancer, nervous system and vessicular transport disorders |
| 09/12/2002 | US20020127540 Detecting modulators of bone morphogenic activities; obtain cells, incubate with modulator, monitor expression of reporter molecules, compare to control |
| 09/12/2002 | US20020127247 Modified clostridial neurotoxins with altered biological persistence |
| 09/12/2002 | US20020127217 A polynucleotides which identify and encode Phosphatidylinositol 4,5-bisphosphate 5-phosphatase (polypeptide) |
| 09/12/2002 | US20020127198 Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| 09/12/2002 | DE10110750A1 Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften Novel Aminodicarbonsäurederivate with pharmaceutical properties |
| 09/12/2002 | CA2440642A1 Dimeric isoflavones |
| 09/12/2002 | CA2440070A1 Pharmaceutical composition made of cannabis extracts |
| 09/12/2002 | CA2439941A1 Secreted proteins |
| 09/12/2002 | CA2439779A1 Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna |
| 09/12/2002 | CA2439205A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439196A1 Nuclear hormone receptor ligand binding domains |
| 09/12/2002 | CA2439192A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2438326A1 Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| 09/12/2002 | CA2437594A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 09/12/2002 | CA2432280A1 Novel glutamate receptor modulatory proteins and nucleic acid molecules and uses therefor |
| 09/12/2002 | CA2431549A1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| 09/11/2002 | EP1239035A1 Novel protein and gene |
| 09/11/2002 | EP1238082A2 Ifn-alpha homologues |
| 09/11/2002 | EP1238077A1 Tnfr/opg-like molecules and uses thereof |
| 09/11/2002 | EP1237902A1 Halogenated sulphamate-, phosphonate-, thiophosphonate-, sulphonate- and sulphonamide- compounds as inhibitors of steroid sulphatase |
| 09/11/2002 | EP1237891A1 Heterocyclic dihydropyrimidines as potassium channel inhibitors |
| 09/11/2002 | EP1237886A1 Heterocyclic derivatives |
| 09/11/2002 | EP1237869A1 Compounds, compositions, and methods for stimulating neuronal growth and elongation |
| 09/11/2002 | EP1237578A2 Micro-cluster liquids and methods of making and using them |
| 09/11/2002 | EP1237575A1 Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder |
| 09/11/2002 | EP1237552A1 Combination of an ergoline and riluzole for preventing and treating motor neuron diseases |
| 09/11/2002 | EP1237548A1 Il-8 receptor antagonists |
| 09/11/2002 | EP1237539A1 Oral solution containing galanthamine and a sweetening agent |
| 09/11/2002 | CN1369015A Recombinant anti-CD 40 antibody and uses thereof |
| 09/11/2002 | CN1368892A Sustained release formulation of peptide |
| 09/11/2002 | CN1368308A Nano medicine for treating lumbago and its preparing process |
| 09/10/2002 | US6448274 Fluoroalkoxy-substituted benzamide dichloropyridinyl N-oxide PDE4 inhibitor |
| 09/10/2002 | US6448264 Use of 5-thio-, sulfinyl- and sulfonylpyrazolo[3,4-b]-pyridines as cyclin dependent kinase inhibitors |
| 09/10/2002 | US6448258 Heterocyclic amine compounds |
| 09/10/2002 | US6448254 Substituted amides, their production and their use |
| 09/10/2002 | US6448243 Serotonin antagonist for treating, ameliorating and preventing spastic paralysis or central muscle relaxants for ameliorating myotonia |
| 09/10/2002 | US6448239 Porphyrin ring metallic complexes that are effective peroxynitrite decomposition catalysts for treatment of diseases involving the accumulation of this oxidant, such as altzeimer's disease |
| 09/10/2002 | US6448231 Presynaptic neurotoxin such as botulinum toxin a |
| 09/10/2002 | US6448054 Locally administering to a specific site a fugetactic agent in an amount effective to repel immune cells |
| 09/06/2002 | WO2002068652A2 Nov-x proteins and nucleic acids encoding same |
| 09/06/2002 | WO2002068650A2 Modified and stabilized gdf propeptides and uses thereof |
| 09/06/2002 | WO2002068476A2 Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders |
| 09/06/2002 | WO2002068415A1 Pyrazole compounds useful as protein kinase inhibitors |
| 09/06/2002 | WO2002068381A2 Aryl-n-cyanoguanidines and methods related thereto |
| 09/06/2002 | WO2002068015A2 Modular infusion device and method |
| 09/06/2002 | WO2002067925A1 Carbamate compounds for use in preventing or treating neurodegenerative disorders |
| 09/06/2002 | WO2002067919A1 Il-8 receptor antagonists |
| 09/06/2002 | WO2002067917A1 Compositions and methods for enhancing drug delivery across and into ocular tissues |
| 09/06/2002 | WO2002067851A2 Method for treating fibrotic diseases or other indications iiic |
| 09/06/2002 | WO2002067760A2 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays |
| 09/06/2002 | WO2002040517A3 M. tuberculosis chaperonin 60.1 and uses thereof |
| 09/06/2002 | WO2002040037A3 M. tuberculosis chaperonin 60.1 and uses thereof |
| 09/06/2002 | WO2001092479A3 Method to determine the differentiation potential of a target cell |
| 09/06/2002 | WO2001012170A3 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
| 09/06/2002 | CA2674673A1 Modified and stabilized gdf propeptides and uses thereof |
| 09/06/2002 | CA2475454A1 Aryl-n-cyanoguanidines and methods related thereto |
| 09/06/2002 | CA2438784A1 Compositions and methods for enhancing drug delivery across and into ocular tissues |
| 09/06/2002 | CA2438238A1 Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders |
| 09/06/2002 | CA2437218A1 Modified and stabilized gdf propeptides and uses thereof |
| 09/06/2002 | CA2434690A1 Proteins, polynucleotides encoding them and methods of using the same |
| 09/06/2002 | CA2433425A1 Method for treating fibrotic diseases or other indications iiic |
| 09/05/2002 | US20020123520 3',5'-cyclic nucleotide phosphodiesterases (PDEs); disease related to eosinophils, such as asthma, chronic bronchitis, and chronic obstructuive pulmonary disease |
| 09/05/2002 | US20020123507 Bicyclic derivatives |
| 09/05/2002 | US20020123493 For therapy and prophylaxis of neuronal damage |
| 09/05/2002 | US20020123492 Beta-amino acid derivatives |
| 09/05/2002 | US20020123488 Pyrazine and triazine derivatives of 1,2,4,5-tetrahydro-Benzo or Thieno [d] azepine |
| 09/05/2002 | US20020123141 Recovering embryonic-like stem cells from a placenta; obtain placenta, drain cord blood, flush placenta with anticoagulant solution, recover cells |
| 09/05/2002 | US20020123099 Highly expressible genes |
| 09/04/2002 | EP1236468A1 Sulfonylaminocarbonyl derivatives for the treatment of nuclear factor-kappa B mediated diseases and disorders |
| 09/04/2002 | EP1235936A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 09/04/2002 | EP1235860A2 G-protein coupled receptors |
| 09/04/2002 | EP1235827A2 Imidazo-pyridine derivatives as ligands for gaba receptors |
| 09/04/2002 | EP1235824A1 Vitamin d analogues |
| 09/04/2002 | EP1235812A2 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 09/04/2002 | EP1235809A1 Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and the use thereof as medicaments |